Tumor cell-derived extracellular vesicles for breast cancer specific delivery of therapeutic P53

Jiao, Yuxuan; Tang, Yunzhi; Li, Yuan; Liu, Chao; He, Jiecheng; Zhang, Lingkun; Guan, Yan‐Qing

doi:10.1016/j.jconrel.2022.07.020

Cited by 20 publications

(9 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 TEXs have inherited specific surface proteins from tumor cells, leading to the tumor-targeting ability. 36 Moreover, TEXs have emerged as promising biomarkers for cancer diagnosis, prognosis, and treatment response prediction, offering non-invasive avenues for monitoring disease progression and guiding therapeutic interventions. 37…”

Section: Source Of Evsmentioning

confidence: 99%

Recent advances in therapeutic engineered extracellular vesicles

Yao,

Zhang,

Wang

2024

Nanoscale

View full text Add to dashboard Cite

show abstract

Section: Source Of Evsmentioning

confidence: 99%

Recent advances in therapeutic engineered extracellular vesicles

Yao,

Zhang,

Wang

2024

Nanoscale

View full text Add to dashboard Cite

show abstract

“…180 Extracellular vesicles (EVs) in the immune microenvironment of osteosarcoma Cancer cell-derived EVs are a group of heterogeneous nanovesicles secreted into the tumor microenvironment or circulation, encapsulating intact organelles, proteins, nucleic acids, and lipids (such as eicosanes, cholesterol, and fatty acids). [181][182][183] Exosomes, a subclass of EVs, are produced by direct outward budding of the cell membrane. 184,185 They induce the proliferation, metastasis, and chemotherapy resistance of osteosarcoma cells.…”

Section: The Immune Microenvironment Of Osteosarcomamentioning

confidence: 99%

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian

Cao

et al. 2023

Bone Res

View full text Add to dashboard Cite

Osteosarcoma, with poor survival after metastasis, is considered the most common primary bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival rate has only shown limited improvement, suggesting that existing therapeutic strategies are insufficient to meet clinical needs. Notably, immunotherapy has shown certain advantages over traditional tumor treatments in inhibiting metastasis. Therefore, managing the immune microenvironment in osteosarcoma can provide novel and valuable insight into the multifaceted mechanisms underlying the heterogeneity and progression of the disease. Additionally, given the advances in nanomedicine, there exist many advanced nanoplatforms for enhanced osteosarcoma immunotherapy with satisfactory physiochemical characteristics. Here, we review the classification, characteristics, and functions of the key components of the immune microenvironment in osteosarcoma. This review also emphasizes the application, progress, and prospects of osteosarcoma immunotherapy and discusses several nanomedicine-based options to enhance the efficiency of osteosarcoma treatment. Furthermore, we examine the disadvantages of standard treatments and present future perspectives for osteosarcoma immunotherapy.

show abstract

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

“…When TPP/P53 was loaded into the EVs, it could target the mitochondria of breast cancer cells, causing signal amplification, inducing the death of these cancer cells, and destroying the tumor tissues with no noticeable toxicity (in vivo). 93 2.1.5. Liposomes.…”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

“…Besides, tumor cell-derived EVs have been examined as specific drug carriers for breast cancer therapy. Jiao et al introduced a novel platform for transferring lipophilic triphenylphosphonium (TPP)-modified therapeutic recombinant P53 (TPP/P53) proteins using breast cancer cell-derived EVs (Figure ). When TPP/P53 was loaded into the EVs, it could target the mitochondria of breast cancer cells, causing signal amplification, inducing the death of these cancer cells, and destroying the tumor tissues with no noticeable toxicity (in vivo) …”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

See 1 more Smart Citation

Advanced Nanosystems for Cancer Therapeutics: A Review

Mohajer

Mirhosseini‐Eshkevari

Ahmadi

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Since cancer has a very complex pathophysiology, existing cancer treatment strategies encounter several challenges such as the lack of specificity/selectivity, induction of multidrug resistance, and possible side effects/toxicity. A wide variety of organic, inorganic, and hybrid nanosystems have been designed with unique magnetic, thermal, mechanical, electrical, and optical properties for targeted cancer therapy. These advanced nanosystems with enhanced bioavailability, biocompatibility, and drug loading capacity have been developed for targeted cancer therapy to reduce toxicity and improve the targeting properties. In this context, challenges persist for their clinical translational studies and enhancement of their therapeutic efficiency as well as the optimization of synthesis conditions and large-scale production. In addition, despite promising preclinical results, the number of nanosystems available to patients is still very low, partly due to a lack of understanding of the differences among animal model species and humans that influence the behavior and functionality of these nanosystems. Regarding this, organ-on-a-chip platforms can significantly help in drug screening and delivery aspects in cancer/tumor cells as well as cancer modeling research; the organs-on-chip approach can also be helpful to analyze the cancer–immune cells interactions. Future studies should focus on the exploration of multifunctional nanosystems with synergistic chemo-photothermal, photothermal/photodynamic, and cancer immunotherapeutic potentials as well as smart nanosystems with theranostic capabilities. Herein, recent advancements pertaining to the applications of advanced nanosystems for cancer therapeutics are deliberated. Current obstacles and limitations hindering the application from research to clinical uses are also discussed while providing recommendations for a more efficient adoption of nanomaterials in the treatment of cancers.

show abstract

Tumor cell-derived extracellular vesicles for breast cancer specific delivery of therapeutic P53

Cited by 20 publications

References 59 publications

Recent advances in therapeutic engineered extracellular vesicles

Recent advances in therapeutic engineered extracellular vesicles

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Advanced Nanosystems for Cancer Therapeutics: A Review

Contact Info

Product

Resources

About